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Abstract
Radiation necrosis (RN) of brain tissue is a serious late complication of 
brain irradiation and recently bevacizumab has been suggested as treat-
ment option of RN. There is a lack of data in the literature regarding 
the effectiveness of bevacizumab for the treatment of RN. The purpose 
of this review was to perform a comprehensive analysis of all reported 
cases using bevacizumab for the treatment of brain RN. In September 
2016, we performed a comprehensive literature search of the following 
electronic databases: PubMed, Web of Science, Scopus and Cochrane 
Library. The research for the review was conducted using a combina-
tion of the keywords “radiation necrosis”, “radiotherapy” and “beva-
cizumab” alongside the fields comprising article title, abstract and 
keywords. Randomized trials, non-randomized trials, prospective stud-
ies, retrospective studies and single case reports were included in the 
review. Our research generated 21 studies and 125 cases where beva-
cizumab had been used for the treatment of RN. The median follow-up 
was 8 months and the most frequent bevacizumab dose used was 7.5 
mg/kg for 2 weeks with a median of four cycles. Low-dose bevacizum-
ab resulted in effectiveness with improvement in both clinical and ra-
diographic response. The median decrease in T1 contrast enhancement 
and in T2/FLAIR signal abnormality was 64% and 60%, respectively. 
A reduction in steroidal therapy was observed in majority of patients 
treated. Based on the data of our review, bevacizumab appears to be a 
promising agent for the treatment of brain RN. Future prospective stud-
ies are required to evaluate the role of bevacizumab in RN and to define 
the optimal scheduling, dosage and duration of therapy.
Keywords: Bevacizumab; Brain metastases; Brain irradiation; Ste-
reotactic radiotherapy
Introduction
With the introduction of new radiation techniques such as in-
tensity-modulated radiation therapy (IMRT) and particle radia-
tion therapy, for the treatment of malignant brain tumors, it is 
possible to provide high absorbed doses to tumor tissue achiev-
ing good rates of tumor control [1-5]. However, the use of high 
dose radiation for the treatment of malignant brain tumors is 
typically at the expense of greater rates of radiation necrosis 
(RN) within the treatment volume. Additionally, stereotactic 
radiosurgery (SRS) achieves good control in metastatic brain 
tumors with the risk of RN, especially in previously irradiated 
patients [6].
The major dose-limiting side effects of radiation therapy 
in the brain irradiation of patients with malignant brain tumors 
or brain metastases are RN, demyelination and vascular dam-
age in the central nervous system (CNS) [7].
RN usually occurs three or more months after radiotherapy 
and the symptoms range from focal to generalized neurologic 
deficits, with a loss of patient autonomy and a negative impact 
on the quality of life [8].
The total radiation dose and volume of irradiated area, as 
well as the fractionation regimen are recognized as the main 
predictive factors of this severe sequela [9-12].
The pathogenesis is associated to endothelial cell dysfunc-
tion with an increased release of vascular endothelial growth 
factor (VEGF) and a subsequent serious damage of the blood-
brain barrier as shown in animal model of RN.
Deregulation of VEGF levels causes vascular permeabil-
ity, brain edema, neuronal demyelination and finally, necrosis 
[13, 14].
Despite the difficulty of discriminating between tumor 
recurrence and radiation-induced tissue damage, magnetic 
resonance imaging (MRI) and magnetic resonance spectros-
copy are considered the gold standard for the diagnosis of 
RN, showing a contrast-enhancing mass with brain white mat-
ter changes and an edema within or adjacent to the site of the 
original tumor [15].
One other non-invasive technique for the diagnosis of RN 
is amino acid positron emission tomography (PET) [16, 17].
Different therapeutic options exist for the treatment of 
RN. Historically, RN has been treated with corticosteroid ther-
apy with poor results and many side effects such as behavioral 
changes, altered sleep patterns and changes in appetite.
Alternatively, the surgical decompression of necrotic areas 
can provide a beneficial palliative effect, despite the radical 
removal of the entire necrotic process being difficult to obtain 
in most cases [18].
Moreover, hyperbaric oxygen, anticoagulation, antiplate-
let antibodies, laser interstitial thermal therapy and high-dose 
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vitamin E have all been employed, albeit with limited efficacy, 
in the treatment of RN [19-22].
Recently, bevacizumab (a humanized murine monoclonal 
antibody against VEGF) has been suggested as a new treat-
ment modality for brain RN [23-44].
There are limited data in the literature regarding the use 
of bevacizumab as a treatment for RN and current data are 
limited to case reports, small case series and one 14-patient 
randomized double-blind study. The purpose of this review 
was to perform a comprehensive analysis of all reported cases 
using bevacizumab for the treatment of cerebral RN. The data 
were compiled in a manner that allowed for an aggregation of a 
larger cohort of patients from a variety of institutions and clini-
cal settings than in previously published articles.
Materials and Methods
Search strategy
In September 2016, we conducted a comprehensive literature 
search of the following electronic databases: PubMed, Web of 
Science, Scopus and Cochrane Library. The databases were 
searched using a combination of keywords pertaining to the 
treatment with bevacizumab of brain RN following brain ir-
radiation. The research for the review was made using a com-
bination of the keywords “radiation necrosis”, “radiotherapy” 
and “bevacizumab” and fields pertaining to article title, ab-
stract and keywords.
Study selection
We included in this systematic review randomized trials, non-
randomized trials, prospective studies and retrospective stud-
ies including patients affected by brain RN and treated with 
bevacizumab. Single case reports and small case series were 
included in this study.
Studies were excluded if there were not diagnoses of RN, 
the cohort studies reported details regarding only radiotherapy 
treatment or treatment outcomes with bevacizumab were not 
reported.
Data extraction and analysis
Data extraction was performed by one reviewer and following 
a review of these articles, another review of all the referenced 
sources was conducted by a second reviewer. Two reviewers 
independently reviewed the abstracts and full texts of all re-
trieved papers to select suitable articles for the review.
We obtained the following information from each report: 
author identification, year of publication, medical centre, 
study design characteristics, study population, number of pa-
tients, age, sex, diagnoses of RN, radiotherapy treatment (RT 
technique, total dose, and dose for fraction), time between 
RT treatment and bevacizumab administration, bevacizumab 
treatment (doses of bevacizumab, number of cycles, frequency 
and administration), clinical response, radiographic response, 
cortisone reduction, median follow-up and toxicities.
Different radiographic criteria were used among the stud-
ies to diagnose RN but in general, they included the appear-
ance of contrast enhancement and vasogenic edema observed 
on MRI, magnetic resonance spectroscopy or amino acid PET 
images.
Statistical analysis
Prior to data gathering, an exploration phase of the data was 
carried out; categorical data were described by frequency and 
percentage, whereas continuous data by mean, median and 
range. If necessary, following data exploration, analysis and 
calculation of frequencies, median and range were performed, 
due to the description of the end-points of review.
Other variables analyzed included the method of diagnosis 
of RN and the percentage change in T1 contrast enhancement 
and T2/FLAIR signal abnormality post-bevacizumab treat-
ment.
All analyses were performed using the SPSS 22 software 
technology.
Results
Research results
Our searches generated a total of 388 results and through a pro-
cess of screening, 21 publications were selected for the review. 
Of the 367 studies excluded, 293 were excluded during the first 
process of screening, after title and abstract analysis; 134 were 
excluded due to duplicate data (same study in more than one 
database research), 179 were excluded because they did not 
represent trials regarding RN and 22 were excluded because 
consisted in review (21) and a letter to the editor (1).
Moreover, 31 studies were excluded following one pro-
cess of full text reading, because they did not fulfil the inclu-
sion criteria (14 studies were excluded because there were no 
diagnoses of cerebral RN and 17 were excluded because re-
ported details concerned only radiotherapy treatment).
Finally, 21 studies fulfilled the inclusion criteria and were 
included in our review; among them, one consisted of a ran-
domized double-blind placebo-controlled trial, 11 were case 
reports and the remaining nine consisted of retrospective stud-
ies and case series.
A flowchart of the systematic literature search process is 
shown in Figure 1.
Patients and treatment characteristics
Our research generated 21 studies and 125 cases with diagno-
ses of RN where bevacizumab had been administered for the 
treatment of RN.
The median age was 57 (range: 8 - 80 years). Six pedi-
atric patients were included in the cohort studies examined. 
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At analyses, 63 patients (50.4%) were male and 62 (49.6%) 
were female (Table 1) [12, 25-44]. The most common tumors 
treated were metastatic brain tumors (61, 49%), glioblastoma 
(28, 22.3%), gliomas (18, 14.5%), meningiomas (seven, 6%), 
pontine glioma (three, 2.5%), fibrous dysplasia of bone (one, 
0.8%), hemangiopericytoma (one, 0.8%), malignant schwan-
noma (one, 0.8%) and pituitary adenoma (one, 0.8%). Three 
patients (2.5%) were treated for arteriovenous malformations.
Regarding the conventional external beam radiation treat-
ment, overall, 98 patients (78.4%) underwent a first course ra-
diotherapy treatment and the mean dosage was 58.9 Gy (range: 
50 - 70 Gy); of them, 28% of the cohort (42 patients) received 
a second course of radiotherapy.
Of the patients who underwent a second course of radia-
tion therapy, 64% received radiosurgery.
Finally, 21% (27 patients) of the cases received radiosur-
gery as the first course of treatment.
The most common sites of necrosis were the frontal lobe 
in 33 cases (27%), temporal lobe in 24 (19%), parietal lobe 
in 15 (12%), brainstem in nine (7%), occipital lobe in eight 
(6%), thalamus in five (4%), cerebellum in five (4%) and basal 
ganglia in four (3%). For 22 patients (18%), the specified site 
of RN was not specified.
Of 125 patients treated, 17 (14%) received a diagnosis of 
RN by tissue biopsy and the remaining 86% were diagnosed 
based on radiographic criteria.
The median time from the end of radiation treatment to 
bevacizumab treatment was 14 months (range: 1 - 180 months; 
Table 2) [12, 25-44].
Previous steroidal therapy for RN was reported in 17 
(80%) of 21 cohort studies and a reduction or stable dosage of 
steroidal therapy after bevacizumab treatment was observed in 
97% of patients.
The median decrease in steroids following bevacizumab 
therapy was 8.6 mg (range: 0 - 24 mg).
The median number of cycles of bevacizumab adminis-
tered was four cycles and the median dosage was 7.5 mg/kg 
every 2 weeks (range from 5 mg/kg every 3 - 4 weeks to 15 
mg/kg every 3 weeks).
The median follow-up after bevacizumab treatment was 8 
months (Table 2).
A clinical benefit with improvement of neurological 
symptoms after bevacizumab administration was observed in 
114 patients (91.2%). Seven patients (5.6%) remained stable 
and four patients (3.2%) have not had a clinical response after 
bevacizumab treatment alongside the progression of signs and 
symptoms following bevacizumab treatment.
Overall, 122 cases (97.6%) had radiographic improve-
ment after treatment with bevacizumab and only three patients 
(2.4%) had radiographic progression of RN at first follow-up.
Pre- and post-treatment imaging decrease in T1 contrast 
enhancement and in T2/FLAIR signal abnormality was spe-
cifically described in nine (42.8%) cohort studies. As shown 
in Table 2, the median decrease in T1 contrast enhancement 
and in T2/FLAIR signal abnormality was 64% and 60%, re-
spectively.
Globally, adverse events were reported in 14 of 21 studies 
analyzed (66%) and the treatment of RN with a low dose of 
bevacizumab was well tolerated in all cohort studies analyzed; 
G3 adverse events were observed in only three cases (2.4%) 
and consisted of pulmonary embolus.
Other adverse events included pulmonary embolus (four 
Figure 1. Flow chart of systematic literature search process. 
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cases), hypertension (six cases), urinary tract infection (one 
case), fatigue (one case), proteinuria (one case), sagittal sinus 
thrombosis (one case), aspiration pneumonia (one case) and 
pneumonia with severe sepsis (one case).
Finally, three patients had small vessel thrombosis, which 
caused ischemic changes.
Discussion
RN of brain tissue is a possible late complication occurring af-
ter radiotherapy treatment and is usually diagnosed at follow-
up imaging or at the appearance of neurological symptoms.
Different therapeutic options are available for the treatment 
of RN; historically, RN has been treated with corticosteroid 
therapy with poor results and many side effects, such as behav-
ioral changes, altered sleep patterns and changes in appetite.
Alternatively, the surgical decompression of a necrotic 
area can provide a beneficial palliative effect [18]. Moreover, 
hyperbaric oxygen, anticoagulation, antiplatelet antibodies, la-
ser interstitial thermal therapy and high-dose vitamin E have 
all been used, albeit with limited efficacy, in the treatment of 
RN [19-22].
Recently, bevacizumab (a humanized murine monoclonal 
antibody against VEGF) has been suggested as a new treat-
ment modality for brain RN.
The rationale of using bevacizumab in patients with RN 
relies on higher VEGF levels in areas of hypoxia and necro-
sis due to endothelial cell dysfunction and a subsequent se-
rious damage of the blood-brain barrier as shown in animal 
model of RN [13, 14]. Hypoxia-inducible factor-1 (HIF-1), a 
heterodimeric transcription factor composed of alpha and beta 
subunits, is an important regulator of angiogenesis through 
the activation of pro-angiogenic factors, among which VEGF 
[22]. In normoxia, the alpha subunit of HIF-1 is rapidly de-
graded, while it remains stable in hypoxic conditions; the non-
degradation of HIF-1 alpha could lead to the over-expression 
of VEGF. As a matter of fact, the highest levels of VEGF ex-
pression have been observed in necrotic or hypoxic areas [24]. 
These preclinical considerations suggest that the use of beva-
cizumab in patients with RN may have a benefit improving in 
clinical and radiographic evaluation with reduction of RN.
Despite poor data in the existing literature, bevacizumab 
treatment appears to be clinical beneficial for patients affected 
by post-RN lesions [25-44].
Gonzalez et al [25], in a retrospective analysis published 
in 2007, demonstrated an improvement in neurological symp-
toms, as well as radiographic improvement, in eight patients 
affected by radiation brain necrosis after treatment with beva-
cizumab at a dose of 5 mg/kg every 2 weeks, or 7.5 mg/kg 
every 3 weeks. The average area change in the T1-weighted 
post-Gd-contrast abnormalities reduction was 48% and in 
FLAIR images 60%, respectively.
Torcuator et al [27] presented the data of six patients with 
biopsy-proven RN treated with low doses of bevacizumab. All 
patients showed radiographic response and an average reduc-
tion of 79% for the T1 post-gadolinium studies and 49% for 
the FLAIR images.
Moreover, Wang et al [34] demonstrated bevacizumab at 
a dose of 7.5 mg/kg every 2 weeks to be effective in the re-
duction of cerebral edema, at radiographic evaluation, with a 
subsequent improvement of clinical symptoms in 17 patients 
affected by a symptomatic brain RN.
Levin et al [35], in a randomized placebo-controlled trial, 
reported the efficacy of bevacizumab at the dose of 7.5 mg/kg 
every 3 weeks for both reducing the necrotic area and improv-
ing clinical symptoms in 14 patients with biopsy-proven RN.
Finally, Sadraei et al [41] published the data of 24 patients 
affected by RN and treated with low doses of bevacizumab, 
with a post-treatment MRI radiographic improvement in 23 of 
24 patients. The average change in the T1-weighted post-con-
trast MRI was a decrease of 48.1% and the average change in 
the fluid-attenuated inversion-recovery images was a decrease 
of 53.7%. There, mean daily dose reduction of dexamethasone 
was 9.4 mg and the treatment with bevacizumab was well tol-
erated, with only one grade 3 adverse event. Similar results 
were reported by other authors [26, 28-33, 36-40, 42-44] in 
their retrospective studies.
The inherent limitations of our study were due to the retro-
spective studies analyzed, the small number of patients reported 
in the studies, the patients having been treated for different con-
ditions, different radiation doses, different radiation modalities 
and with limited follow-up after bevacizumab therapy. Further-
more, the diagnosis of RN was made by radiologic evaluation 
in the majority of the studies analyzed in this review and the 
patients were treated in different institutions and countries.
Furthermore, there is a publication bias present, because 
only patients who responded to bevacizumab were likely to be 
included in the published literature.
Overall, based on our results of the review conducted, a 
low dose of bevacizumab appears to be efficacious for reduc-
ing RN in patients affected by brain metastases and RN after 
radiotherapy treatment, seemingly without any risk of clinical 
complications.
Conclusions
Based on the data of our review, low-dose bevacizumab ap-
pears to be a promising agent for the treatment of brain RN, as 
well as an anti-cancer drug.
Currently, the optimal scheduling and treatment duration 
has not yet been established.
Nevertheless, a significant amount of recurrence has been 
described several months after bevacizumab discontinuation, 
indicating that repeated cycles may be warranted in the ab-
sence of contraindications.
Future prospective studies are required to properly evalu-
ate the role of bevacizumab as an efficacious agent against 
post-RN as well as to define the optimal scheduling, dosage 
and duration of therapy.
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